|Bid||191.40 x 200|
|Ask||191.75 x 100|
|Day's Range||191.06 - 198.39|
|52 Week Range||163.31 - 210.19|
|Beta (3Y Monthly)||1.36|
|PE Ratio (TTM)||59.68|
|Earnings Date||Jan 30, 2019 - Feb 4, 2019|
|Forward Dividend & Yield||5.28 (2.74%)|
|1y Target Est||204.80|
Amgen Inc. (AMGN) has informed the market Friday after closing bell that the board of directors of the company has authorized the payment of a quarterly dividend for the first trimester of fiscal 2019. The company will pay shareholders a cash dividend of $1.45 per share, reflecting a 9.8% increase from the previous one. Warning! GuruFocus has detected 2 Warning Signs with AABA.
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 5.7% in the 12 months ending October 26 […]
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
Amgen Inc. said late Friday its board of directors has declared a dividend of $1.45 a share for the first quarter of 2019. The dividend is payable March 8 to shareholders of record on Feb. 15. That represents a 10% increase from what Amgen paid in each of the previous four quarters. Shares of Amgen rose 0.2% in the extended session Friday after ending the regular trading day down 3.8%.
THOUSAND OAKS, Calif., Dec. 7, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the first quarter of 2019. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives.
Critics of high drug prices are launching a new line of attack against manufacturers of the medicines, faulting the firms for using savings from the tax overhaul to buy back shares rather than lower prices. The attacks began in October, when more than a dozen Democrats in the House of Representatives sent letters to five big pharmaceutical companies saying they had benefited from recent tax cuts but kept charging high prices. The letters singled out certain drugs whose list prices had increased and asked their manufacturers for details about price changes and the costs of research and advertising.
Will the yield curve invert, with short-term interest rates pushing their way above long-term interest rates … a relatively rare scenario that’s all too often associated with a troubled economy? A true inverted yield curve has not happened yet, but as of right now we’re as close to an inverted yield curve as we’ve been in a decade. Translation: It sure couldn’t hurt to go ahead and make plans for an inverted yield curve, just in case that’s how things take shape.
This week, focus was on data presented at the annual conference of the American Society of Hematology from Dec 1-4. Apart from this, the regular pipeline updates were also in focus in the biotech sector.
The FDA accepts and grants Priority Review to Roche's (RHHBY) sBLA for Tecentriq in combination with carboplatin and etoposide for the initial treatment of patients withextensive-stage small cell lung cancer.
Amgen's (AMGN) BiTE immunotherapy candidates, namely AMG 420 and AMG 330 show positive results in early-stage studies. AMG 420 gets a fast track designation from the FDA
How Is Teva Pharmaceutical Positioned in 2018? On September 14, Teva Pharmaceutical (TEVA) issued a press release announcing FDA approval of Ajovy, a humanized monoclonal antibody and anti-calcitonin gene-related peptide (or CGRP) therapy for migraine prevention indication. Teva Pharmaceutical expects to secure regulatory approval from the European Commission (or EC) for Ajovy in migraine prevention indication in H1 2019.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 3) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...
Amgen Inc (AMGN.O), updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer. Six patients were still responding at 7.5 months of follow-up, according to research presented in San Diego at the annual meeting of the American Society of Haematology (ASH). Amgen said AMG420, which targets a protein linked to multiple myeloma known as BCMA, has been given fast track status by the U.S. Food and Drug Administration.
Amgen Inc, updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer. Six patients were still responding at 7.5 months of follow-up, according to research presented in San Diego at the annual meeting of the American Society of Hematology (ASH). Amgen said AMG420, which targets a protein linked to multiple myeloma known as BCMA, has been given fast track status by the U.S. Food and Drug Administration.
THOUSAND OAKS, Calif., Dec. 3, 2018 /PRNewswire/ -- Amgen (AMGN) today announced the first clinical results from studies evaluating investigational novel bispecific T cell engager (BiTE®) immunotherapies AMG 420 and AMG 330. In two separate Phase 1 dose escalation studies, AMG 420, which targets B-cell maturation antigen (BCMA), and AMG 330, which targets CD33, provided early evidence of tolerability and anti-tumor activity in patients with relapsed and/or refractory multiple myeloma and relapsed or refractory acute myeloid leukemia (AML), respectively.
THOUSAND OAKS, Calif. , Dec. 3, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Citi Global Healthcare Conference at 12:35 p.m. ET on Thursday , Dec. 6, 2018, in New York City . Elliott M. ...
Every investor in Amgen Inc (NASDAQ:AMGN) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual to see insiders Read More...
The FDA's BRUDAC committee will review Amgen (AMGN) and its European partner UCB's BLA for Evenity so that the candidate gets approved for treating osteoporosis in postmenopausal women.
Large-cap pharma stocks are seeing some upward momentum and are on track to finish the year with handsome gains. As the year draws to a close, it remains to be seen if these stocks can sustain the ongoing ...
Pfizer on Friday joined a slew of pharmaceutical stocks with licensing deals to launch a Humira biosimilar under a deal with AbbVie.